Genexine, Inc.
Research Genexine, Inc. (095700.KQ) on Bullrun: market cap KRW 120.29B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker095700.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 120.29B
- Financial periodQ2 2026
- RevenueKRW 972.21M
- Net income-KRW 26.27B
- Free cash flow-KRW 10.84B
- Gross margin-99.5%
Valuation Snapshot
latest market cap is KRW 120.29B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 120.29B | n/a | n/a | n/a |
Dividend history
About Genexine, Inc.
Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally. The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses in the human body to fight viral infection and cancer cells.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Genexine, Inc.'s market cap?
Genexine, Inc.'s market capitalization is KRW 120.29B.
What does Genexine, Inc. do?
Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally. The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses in the human body to fight viral infection and cancer cells.